Dr Aleix Prat
Dr. Aleix Prat is currently the Head of the Medical Oncology of Hospital Clínic of Barcelona (Spain), Associate Professor of the University of Barcelona and the Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at August Pi i Sunyer Biomedical Research Institute (IDIBAPS). He obtained his MD degree in 2003 from the University of Barcelona and completed a medical oncology fellowship in 2008 at Vall d´Hebron Institute of Oncology (VHIO). In 2008, Dr. Prat became a postdoctoral research associate at the Lineberger Comprehensive Cancer Center (University of North Carolina at Chapel Hill, USA) in the Laboratory of Prof. Charles M. Perou. In 2012, he returned to Barcelona as the Head of the Translational Genomics Group at VHIO and more recently, he moved to Hospital Clínic and IDIBAPS. Dr. Prat is a clinical scientist with a longstanding research interest in the clinical application of laboratory findings in breast cancer, with a particular interest in gene expression and the clinical implications of different intrinsic molecular subtypes of breast cancer. He designs and leads clinical trials of novel drugs and approaches, and is currently the scientific coordinator of SOLTI, a Spanish breast cancer cooperative group. Recently he has been recently named as a Member of Executive Committee of the The Breast International Group (BIG), an international non-profit organisation that includes more than 56 cooperative groups from around the world, more than 10,000 experts and it is linked to more than 3,000 hospitals. Its main goal is to promote clinical and translational research in breast cancer. Dr. Prat received the International Prize for Breast Cancer Research (Padova, Italy) for his scientific discoveries regarding the characterization and clinical value of the intrinsic subtypes. Since 2007, he has actively taken part in a total of 105 publications (H-score of 33), with a total of 5,486 citations and 45 communications in international congresses. Finally, Dr. Prat has received competitive funding from different sources including Susan Komen Foundation, Breast Cancer Research Foundation and the Spanish Ministry of Health.